These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35159208)

  • 1. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications.
    Pereira F; Ferreira A; Reis CA; Sousa MJ; Oliveira MJ; Preto A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159208
    [No Abstract]   [Full Text] [Related]  

  • 2. Highlights on the Role of
    Hafezi S; Saber-Ayad M; Abdel-Rahman WM
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
    Moss DY; McCann C; Kerr EM
    Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the ERβ/HER Oncogenic Network in
    Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer.
    Carr RM; Fernandez-Zapico ME
    Cancer Discov; 2020 Jul; 10(7):910-912. PubMed ID: 32611735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune modulatory effects of oncogenic KRAS in cancer.
    Hamarsheh S; Groß O; Brummer T; Zeiser R
    Nat Commun; 2020 Oct; 11(1):5439. PubMed ID: 33116132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.
    Kerk SA; Papagiannakopoulos T; Shah YM; Lyssiotis CA
    Nat Rev Cancer; 2021 Aug; 21(8):510-525. PubMed ID: 34244683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
    Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
    Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS inhibition in metastatic colorectal cancer: An update.
    Nusrat M; Yaeger R
    Curr Opin Pharmacol; 2023 Feb; 68():102343. PubMed ID: 36638742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
    Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
    [No Abstract]   [Full Text] [Related]  

  • 15. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.
    Bartolini A; Cardaci S; Lamba S; Oddo D; Marchiò C; Cassoni P; Amoreo CA; Corti G; Testori A; Bussolino F; Pasqualini R; Arap W; Corà D; Di Nicolantonio F; Marchiò S
    Clin Cancer Res; 2016 Oct; 22(19):4923-4933. PubMed ID: 27143691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Inflammation and KRAS Mutation in Lung Cancer.
    Keohavong P; Peter Di Y
    Adv Exp Med Biol; 2021; 1303():71-87. PubMed ID: 33788188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation.
    Brubaker DK; Paulo JA; Sheth S; Poulin EJ; Popow O; Joughin BA; Strasser SD; Starchenko A; Gygi SP; Lauffenburger DA; Haigis KM
    Cell Syst; 2019 Sep; 9(3):258-270.e6. PubMed ID: 31521603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines: Targeting KRAS-driven cancers.
    Zhang Y; Ma JA; Zhang HX; Jiang YN; Luo WH
    Expert Rev Vaccines; 2020 Feb; 19(2):163-173. PubMed ID: 32174221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.